- Home
- LUCY vs NXTC Comparison
LUCY vs NXTC Comparison
Compare LUCY & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- NXTC
- Stock Information
- Founded
- LUCY 2017
- NXTC 2015
- Country
- LUCY United States
- NXTC United States
- Employees
- LUCY N/A
- NXTC N/A
- Industry
- LUCY Ophthalmic Goods
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- NXTC Health Care
- Exchange
- LUCY Nasdaq
- NXTC Nasdaq
- Market Cap
- LUCY 8.9M
- NXTC 13.9M
- IPO Year
- LUCY 2022
- NXTC 2019
- Fundamental
- Price
- LUCY $3.19
- NXTC $0.49
- Analyst Decision
- LUCY
- NXTC Strong Buy
- Analyst Count
- LUCY 0
- NXTC 2
- Target Price
- LUCY N/A
- NXTC $3.50
- AVG Volume (30 Days)
- LUCY 2.5M
- NXTC 141.9K
- Earning Date
- LUCY 05-13-2025
- NXTC 05-01-2025
- Dividend Yield
- LUCY N/A
- NXTC N/A
- EPS Growth
- LUCY N/A
- NXTC N/A
- EPS
- LUCY N/A
- NXTC N/A
- Revenue
- LUCY $1,707,470.00
- NXTC N/A
- Revenue This Year
- LUCY $542.00
- NXTC N/A
- Revenue Next Year
- LUCY $148.54
- NXTC N/A
- P/E Ratio
- LUCY N/A
- NXTC N/A
- Revenue Growth
- LUCY 22.75
- NXTC N/A
- 52 Week Low
- LUCY $1.57
- NXTC $0.22
- 52 Week High
- LUCY $25.40
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- LUCY 61.71
- NXTC 55.20
- Support Level
- LUCY $2.80
- NXTC $0.45
- Resistance Level
- LUCY $3.40
- NXTC $0.52
- Average True Range (ATR)
- LUCY 0.36
- NXTC 0.05
- MACD
- LUCY 0.11
- NXTC 0.01
- Stochastic Oscillator
- LUCY 79.98
- NXTC 66.47
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.